Crawford Lake Capital Management LLC trimmed its holdings in shares of NeuroDerm Ltd. (NASDAQ:NDRM) by 93.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,123 shares of the biotechnology company’s stock after selling 226,553 shares during the quarter. Crawford Lake Capital Management LLC owned about 0.06% of NeuroDerm worth $452,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. OppenheimerFunds Inc. bought a new position in NeuroDerm during the first quarter worth about $7,588,000. Bailard Inc. increased its position in NeuroDerm by 9.5% during the first quarter. Bailard Inc. now owns 109,000 shares of the biotechnology company’s stock worth $2,894,000 after acquiring an additional 9,500 shares during the period. HighTower Advisors LLC bought a new position in NeuroDerm during the first quarter worth about $242,000. Bank of Montreal Can bought a new position in NeuroDerm during the first quarter worth about $266,000. Finally, Oppenheimer & Co. Inc. bought a new position in NeuroDerm during the first quarter worth about $223,000. 52.39% of the stock is currently owned by institutional investors and hedge funds.
NeuroDerm Ltd. (NASDAQ:NDRM) traded up 0.065% during trading on Tuesday, reaching $38.775. 1,157,401 shares of the company’s stock traded hands. The company’s 50 day moving average is $38.64 and its 200-day moving average is $29.62. NeuroDerm Ltd. has a 52-week low of $15.20 and a 52-week high of $38.85. The stock’s market cap is $1.02 billion.
A number of research firms recently commented on NDRM. CIBC raised shares of NeuroDerm from a “market perform” rating to an “outperform” rating and set a $42.00 price target on the stock in a research report on Wednesday, June 14th. Zacks Investment Research raised shares of NeuroDerm from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Roth Capital lowered shares of NeuroDerm from a “buy” rating to a “neutral” rating and raised their price target for the stock from $33.00 to $39.00 in a research report on Wednesday, August 2nd. Deutsche Bank AG began coverage on shares of NeuroDerm in a research report on Friday, July 21st. They set a “buy” rating and a $47.00 price target on the stock. Finally, BidaskClub raised shares of NeuroDerm from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $44.13.
NeuroDerm Company Profile
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.